臺灣博碩士論文加值系統

中文摘要
研究目的
黏膜相關淋巴組織淋巴瘤是個少見的惡性腫瘤，雖然對於胃部黏膜相關淋巴組織淋巴瘤的發生與治療有越來越多的報告，但是在非胃部黏膜相關淋巴組織淋巴瘤的臨床表現、治療方式以及長期的病人存活，目前所知不多。

研究方法
本研究回顧性收集肺臟與唾液腺的黏膜相關淋巴組織淋巴瘤病人之臨床資料，病人臨床資訊收集時間從西元1993年到2014年止。為了更加了解黏膜相關淋巴組織淋巴瘤的特性，在本研究中也收集肺臟瀰漫性大B細胞淋巴瘤作為對照組。

研究結果
1. 肺臟黏膜相關淋巴組織淋巴瘤與肺臟瀰漫性大B細胞淋巴瘤的臨床比較
共有32位肺臟黏膜相關淋巴組織淋巴瘤病人以及17位肺臟瀰漫性大B細胞淋巴瘤病人，在五年無惡化存活期以及疾病整體存活，肺臟黏膜相關淋巴組織淋巴瘤都相對於瀰漫性大B細胞淋巴瘤族群來的比較好(p=0.004 以及p=0.045)。此外在肺臟黏膜相關淋巴組織淋巴瘤族群中，以治療方式做治療族群區分，接受手術治療者相比於沒有手術治療者，在無疾病存活似乎有傾向來的比較好，但統計學上沒有達到意義(p=0.176)。
2. 唾液腺黏膜相關淋巴組織淋巴瘤
共有14位唾液腺黏膜相關淋巴組織淋巴瘤的病人可以納入分析。治療方式與疾病臨床分期有高度相關，Ann-Arbor分期IE共有7位病人，其中有六位病人接受腮腺切除術，一位病人接受放射治療；有七位病人的分期是IIE、IIIE或是IVE，這些病人治療方式因為已經有淋巴結轉移，主要以化學治療為主。僅有一位病人因淋巴瘤惡化之故死亡，若以治療做區分，手術治療的病人似乎比化學治療的病人來的容易復發(p=0.241)，雖然人數過少而達不到統計學上的意義。

研究結論
肺臟與唾液腺黏膜相關淋巴組織淋巴瘤的長期存活很好，雖然最佳的治療方式尚未證實，但從本回顧性研究發現，局部手術治療在肺臟黏膜相關淋巴組織淋巴瘤是個不錯的選擇，但在唾液腺黏膜相關淋巴組織淋巴瘤族群，似乎復發率偏高。

Purpose
Mucosa associated lymphoid tissue (MALT) lymphoma is a rare disease. Although more and more information of gastric MALT lymphoma is known, the clinical characteristics, treatment modalities, and outcomes of non-gastric MALT lymphoma are not well elucidated.

Methods
A retrospective review study of primary pulmonary and salivary gland MALT lymphoma cases at a single institution from 1993 to 2014 was conducted. For better comparison, a more aggressive lymphoma type, diffuse large B cell lymphoma, of primary lung origin was included into this study.

Results
1. Pulmonary mucosa associated lymphoid tissue lymphoma
We successfully collected clinical data of pulmonary MALT lymphoma. In addition, the data of pulmonary diffuse large B cell lymphoma (DLBCL) were collected as comparison. Thirty-two pulmonary MALT lymphoma patients and seventeen pulmonary DLBCL patients are included in this study. The 5-year event free survival and overall survival are better in MALT lymphoma group (p=0.004 and p=0.045) compared with DLBCL group. We also compared overall survival by different treatment modalities in MALT lymphoma group. Patients treated with surgery had a trend of better survival compared with other non-surgery(p=0.176).
2. Salivary gland mucosa associated lymphoid tissue lymphoma
Clinical data of parotid MALT lymphoma was collected. Fourteen patients are included into this study. Treatment modalities were stratified by Ann-Arbor stage. Seven stage IE patients were treated with parotidectomy or curative radiation therapy. Seven patients with stage IIE, IIIE or IVE were treated with chemotherapy with or without Rituximab. Thirteen patients are alive till the end of follow-up. Only one patient died of progression of lymphoma. However, a trend of easy relapse in stage IE parotid lymphoma treated with parotidectomy(p=0.241).

Conclusions
MALT lymphoma of pulmonary and salivary gland origin has long overall survival compared with other types of lymphoma of the same origin. Although local surgery is an effective treatment for pulmonary and salivary gland MALToma, easy relapse is found in salivary gland MALToma. More studies are needed to elucidate this phenomenon.

目 錄

口試委員會審定書…………………………………………………………………………………………………….I
誌謝…………………………………………………………………………………………………………………………..II
中文摘要…………………………………………………………………………………………………………………..III
英文摘要…………………………………………………………………………………………………………………..V

第壹章 緒論………………………………………………………………….…….1
第一節 研究背景……………………………………………………….…….1
第二節 研究目的……………………………………………………….…….7
第貳章 研究方法與材料……………………………………………..8
第一節 研究設計………………………………………………………….….8
第二節 研究方法……………………………………………………….…….8
第三節 統計方法……………………………………………………….….…9
第參章 結果……………………………………………………….………………10
第肆章 討論……………………………………………………………………….16
第伍章 展望……………………………………………………………………….21
第陸章 論文英文簡述(summary)………………………………23
第柒章 參考文獻……………………………………………………………….32
第捌章 表格與附圖………………………………………………………….44

1.Aaron J. Feinstein, Maria M. Ciarleglio, Xiangyu Cong, Michael D. Otremba, Benjamin L. Judson. Parotid Gland Lymphoma: Prognostic Analysis of 2140 Patients. Laryngoscope, 2013; 123:1199–1203.

2.Adam J. Olszewski, Eric S. Winer , Jorge J. Castilloc. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leukemia Research 2014；38: 866–873.

3.Adreas Rosenwald, German Ott, Stephan Stilgenbauer, et al: Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas. American Journal of Pathology 1999；155(6):1817-1821.

4.Alejandro Vazquez, Mohemmed N. Khan, Saurin Sanghvi, Neal R. Patel, Joseph L. Caputo, Soly Baredes, Jean Anderson Eloy. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: A population-based study from 1994 to 2009. HEAD & NECK 2015; January: 18-22.

5.Amar Lal, Yasmin Bhurgri, Irfan Vaziri, Nida B. Rizvi, Aliyah Sadaf, Saba Sartajuddin, Mohammed Islam, Pawan Kumar, Salman Adil, Ghulam Nabi Kakepoto, Nehal Masood, Mohammed Khurshed, Amyn Alidina. Extranodal Non-Hodgkin’s Lymphomas - A Retrospective Review of Clinico-Pathologic Features and Outcomes in Comparison with Nodal Non-Hodgkin’s Lymphomas. Asian Pacific J Cancer Prev. 2008；9:453-458.

6.Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998；9: 717-20.

7.Aoki, D., Ueno, S., Kubo, F., Aikou, T. et al Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. Anticancer Research. 2005；25: 133–138

8.Auer IA, Gascoyne RD, Connors JM, et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncology. 1997；8:979-985.

9.Barbara Kiesewetter and Markus Raderer et al: Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 2013；122(8):1350-1357.

10.Borie R, Wislez M, Thabut G. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009；34: 1408-1416.

11.Brito ZP, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón FJ, Zamora M, Casanovas A, Ramos-Casals M et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017；10(1):90.

12.Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lymphomas. Hematology Am Soc Hematol Educ Program. 2001；241-58.

13.Cerroni L, Z¨ ochling N, P¨utz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997；24(8):457-46.

14.Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

15.Christian Drosten, Marcus Panning, and Stefanie Kramme. Detection of Mycobacterium tuberculosis by Real-Time PCR Using Pan-Mycobacterial Primers and a Pair of Fluorescence Resonance Energy Transfer Probes Specific for the M. tuberculosis Complex. Clinical Chemistry 2003; 49(10): 1659~.

16.Davies, J.C. & Rubin, B.K. et al. Emerging and unusual gram-negative infections in cystic fibrosis. Seminars in Respiratory and Critical Care Medicine 2007；28: 312–321.

17.De Baets, F., Schelstraete, P., Van Daele, S., Haerynck, F. & Vaneechoutte, M. et al. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. Journal of Cystic Fibrosis 2007；6; 75–78.

18.De Re V, de Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G, et al. Salivary gland B cell lymphoproliferative disorders in Sjogren’s syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin’s lymphomas. Eur J Immunol. 2002; 32:903–10.

19.Dierlamm J, Baens M, Wlodarska I, et al: The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosaassociated lymphoid Blood. 1993；93(11):3601-9.

20.Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008；111: 4029–4038.

21.Evangelia B, Issa JD, Michael V, Haralampos M.M, Hematologic manifestations and predictors of lymphoma dvelopment in primary Sjogren Syndrome. Medicine. 2009；88: 284-293.

22.Fabris M, Dolcetti R, Pasini E, et al, High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with Sjögren''s syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. Clin Exp Rheumatol. 2014；32(1); 61-5.

23.Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000；69; 993–997.

24.Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004；96(8):586-594.

25.Ferreri AJ, Dolcetti R, Dognini GP, et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int J Cancer. 2008；123:1089-1093.

26.Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Ponzoni M. Chlamydial infection: the link with ocular adnexal lymphomas. Nat Rev Clin Oncol. 2009；6:658-669.

27.Ferreri AJ, Sassone M, Kiesewetter B, et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015；26:1760-1765.

28.Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972；29:252– 60.

29.Gisbert JP, Garc´ıa-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003；125(6):1723-1732.

30.Gonzàlez N, Xicoy B, Olivé A, Jové J, Ribera JM, Feliu E. Systemic lupus erythematosus in a patient with primary MALT lymphoma of the larynx. Ear Nose Throat J. 2009 Aug;88(8):E4-5.

31.Goules AV, Kapsogeorgou EK2, Tzioufas AG. Insight into pathogenesis of Sjögren''s syndrome: Dissection on autoimmune infiltrates and epithelial cells. Clin Immunol. 2017 Mar 19. pii: S1521-6616(16):30696-9.

32.Govi S, Dognini GP, Licata G, et al. Sixmonth oral clarithromycin regimen is safe and active in extranodal marginal zone Bcell lymphomas: final results of a singlecentre phase II trial. Br J Haematol. 2010；150:226-229.

33.Graham BB, Mathisen DJ, Mark EJ, Takvorian RW. Primary pulmonary lymphoma. Ann Thorac Surg. 2005；80(4):1248-53.

34.Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361–1392.

35.Hu YH, Hsiao LT, Yang CF. Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin’s lymphoma: the single-institute experience in Taiwan. Ann Hematol. 2009；88:839–846.

36.Huang Hui, Lu Zhi-wei, Jiang Chun-guo, Li Ji, XuKai, Xu Zuo-jun. Clinical and prognostic characteristics of pulmonary mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 23 cases in a Chinese population. Chinese Medical Journal. 2011；124(7):1026–1030.

37.Inadome Y, Ikezawa T, Oyasu R, Noguchi M., et al: Malignant lymphoma of bronchus-associated lymphoid tissue (BALT) coexistent with pulmonary tuberculosis. Pathol Int. 2001；51(10):807-11.

38.Isaacson PG, Mu¨ ller-Hermelink HK, Piris MA, et al. Extranodal arginal zone B-cell lymphoma of maucosa-associated lymphoid tissue (MALT lymphoma). In: Press I, Jaffe ES, Harris NL, et al. Pathology and Genetics: Tumours of Haematopoietic Tissues. World Health Organization Classification of Tumours. Lyon, WHO. 2001; pp. 157–160.

39.Isaacson PG, Chott A, Nakumura S, et al. Extranodal marginal cell lymphoma of mucosaassociated tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008；8214-219.

40.James O. Armitage, et al. Staging Non-Hodgkin Lymphoma. CA Cancer J Clin. 200；555:368–376.

41.Jung Han Kim, Se-Hoon Lee, Jinny Park, Ho Young Kim, Soon Il Lee, Joon-Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park. Primary Pulmonary Non-Hodgkin''s Lymphoma. Jpn J Clin Oncol. 2004；34 (9): 510-514.

42.Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease: A review of 201 cases. Cancer. 1974; 3: 850–858.

43.Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978；89: 888–892.

44.Khalilpour A, Kazemzadeh-Narbat M, Tamayol A, Oklu R, Khademhosseini A et al. Biomarkers and diagnostic tools for detection of Helicobacter pylori. Appl Microbiol Biotechnol. 2016 ；Apr 15. [Epub ahead of print]

45.Kiesewetter B, Raderer M, : Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013；122(8);1350-7.

46.Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013；98:353-356.

47.Kuo SH, Chen LZ, Cheng AL, et al: Nuclear Expression of BCL10 or Nuclear Factor Kappa B Predicts Helicobacter pylori–Independent Status of Early-Stage, High-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphomas. J Clin Oncol. 2004；22:3491-3497.

48.Kuo SH, Chen LZ, Cheng AL, et al: Overexpression of B cell–activating factor of TNF family (BAFF) is associated with Helicobacter pylori–independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood. 2008；112:2927-2934.

49.Kuo SH, Yeh KH, Chen LT, et al. Helicobacter pylori CagA translocation is closely associated with the expression of CagA signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Am J Surg Pathol. 2015；39:761-766.

50.Levine EG, Arthur DC, Machnicki J, et al: Four new recurring translocations in non-Hodgkin lymphoma. Blood. 1989；74:1796-1800.

51.Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004；350(3):239-248.

52.L’Hoste RJ, Fillipa DA, Lieberman PH, Bretsky S. Primary pulmonary lymphoma. A clinicopathologic analysis of 36 cases. Cancer. 1984；54:1396–406.

53.Lin WC, Tsai HF, Kuo SH, Wu MS, Lin CW, Hsu PI, Cheng AL, Hsu PN, Translocation of Helicobacter pylori CagA into Human B Lymphocytes, the Origin of Mucosa-Associated Lymphoid Tissue Lymphoma. Cancer Res. 2010; 70(14): 5740–8.

54.Lin YC, Kau HC, Kao SC, Hsu WM, Tsai CC. Systemically disseminated extranodal marginal zone B-cell lymphoma of lacrimal gland in a patient with systemic lupus erythematosus. Ophthal Plast Reconstr Surg. 2007 Jan-Feb；23(1):72-3.

55.Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001；357:39-40.

56.Liu H, Ye H, Dogan A, et al: t(11;18)(q21; q21) is associated with advanced mucosa associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 2001；98:1182-1187.

57.Lixia Liu, Tom Coenye, Jane L. Burns, Paul W. Whitby, Terrence L. Stull, and John J. LiPuma1. Ribosomal DNA-Directed PCR for Identification of Achromobacter (Alcaligenes) xylosoxidans Recovered from Sputum Samples from Cystic Fibrosis Patients. Journal of Clinical Microbiology. 2002; 40(4): 1210–1213.

58.Maeda A, Hayama M, Nakata M, Masaki H, Tanemoto K. Mucosa-associated lymphoid tissue lymphoma in the thymus of a patient with systemic lupus erythematosus. Gen Thorac Cardiovasc Surg. 2008 Jun;56(6):288-91.

59.Malaty HM, Epidemiology of Helicobacter pylori
infection. Best Pract Res Clin Gastroenterol. 2007；21:205–214.

60.Manuel Ramos-Casals, Luca La Civita, et al. Characterization of B Cell Lymphoma in Patients With Sjo¨gren’s Syndrome and Hepatitis C Virus Infection Arthritis & Rheumatism (Arthritis Care & Research). 2007; 57(1): 161–170.

61.Marlene Troch, Michael Formanek, Berthold Streubel, Leonhard Mu¨ llauer, Andreas Chott, Markus Raderer, Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: a retrospective single-center analysis of 28 cases. HEAD & NECK. 2011 June: 763-767.

62.Neri N, Jesús Nambo M, Avilés A. Diffuse large B-cell lymphoma primary of lung. Hematology. 2011；16(2):110-2.

63.P Adam, P Czapiewski, Du MQ et al. Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. Br J Haematol. 2014；164(6):804-10.

64.Pier Luigi Zinzani, Cinzia Pellegrini, Letizia Gandolfi, Beatrice Casadei, Enrico Derenzini, Alessandro Broccoli, Federica Quirini, Lisa Argnani, Stefano Pileri, Monica Celli, Stefano Fanti, Venerino Poletti, Vittorio Stefoni and Michele Baccarani. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. Hematol Oncol. 2013；31: 183–188.

65.Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, Roodenburg JL, Kallenberg CG, Vissink A, van Imhoff GW. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren''s syndrome: a retrospective clinical study. J Rheumatol. 2011 Oct;38(10):2198-208.

66.Pract Res Clin Gastroenterol 21:205–214McMahon BJ, Bruce MG, Parkinson AJ. et al. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect. 2016；144(2):225-33.

67.Prateek Bhatia, Reena Das, Jasmina Ahluwalia, Pankaj Malhotra, Neelam Varma, Subhash Varma, Amita Trehan, Ram Kumar Marwaha. Hematological Evaluation of Primary Extra Nodal Versus Nodal NHL: A Study from North. IndiaIndian J Hematol Blood Transfus. 2011；27(2):88–92.

68.Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosaassociated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006；24:3136-3141.

69.Raso, T., Bianco, O., Grosso, B., Zucca, M. & Savoia, D. et al. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2008；116; 837–841.

70.Ronne Hansen, C., Pressler, T., Hoiby, N. & Gormsen, M. et al. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. Journal of Cystic Fibrosis. 2006；5: 245–251.

71.Ruiz-Arguelles GJ, Mercado-Diaz MA, De Ponce-Leon S, Perez-Tamayo R. Studies on lymphomata III: lymphomata, granulomata and tuberculosis. Cancer. 1983; 52: 258–262.

72.Ruskon FA, Fischbach W, Aleman BM, et al; EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011；60(6):747-758.

73.Saltzstein SL. Pulmonary malignant lymphomas and pseudolymphomas: Classification, therapy, and prognosis. Cancer. 1963；16:928-955.

74.Simona Sammassimo, Giancarlo Pruneri, Giovanna Andreola, Juan Montoro, Sara Steffanoni, Grzegorz S. Nowakowski, Sara Gandini, Mara Negri, Thomas M. Habermann, Markus Raderer, Zhi-Ming Li, Pier Luigi Zinzani, Patrick Adam, Emanuele Zucca and Giovanni Martinelli. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2016；34: 177–183.

75.Somanath Padhi,Tara Roshni Paul, Sundaram Challa, Aruna K Prayaga, Senthil Rajappa, Raghunadharao D, Rajlaxmi Sarangi: Primary Extra Nodal Non Hodgkin Lymphoma: A 5 Year Retrospective Analysis. Asian Pacific J Cancer Prev. 2012；13 (10): 4889-4895.

76.Streubel B, Simonitsch-Klupp I, Mullauer L, et al: Variable frequencies of MALT lymphoma associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18:1722-1726, 2004

77.Victor Shing Howe To, Jimmy Yu Wai Chan, Raymond K. Y. Tsang, and William I. Wei: Review of salivary gland neoplasms. ISRN Otolaryngology. 2012；1–6.

78.Wang HP, Zhu YL, Shao W, Role of Helicobacter pylori virulence factor cytotoxin-associated gene A in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2013；19(45): 8219-8226.

79.Wang D, You Y, Case SM, et al: A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol 2002；3:830-835.

80.Wang HP, Zhu YL, Shao W, Role of Helicobacter pylori virulence factor cytotoxin-associated gene A in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2013；19(45): 8219-8226.

81.Wohrer S, Troch M, Streubel B, et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia. 2007；21(8):1812-1818.

82.Wother S AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991；338:1175-1176.

83.Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases Diagnostic Pathology. 2011；6(77): 4895.

84.Yeh KH, Kuo SH, Cheng AL, et al: Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori–independent status of low-grade gastric mucosa–associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood. 2015；106:1037-1041.